BACKGROUND: The nonsteroidal estrogen equol occurs as diastereoisomers, S-(-)equol and R-(+)equol, both of which have significant biological actions. S-(-)equol, the naturally occurring enantiomer produced by 20-30% of adults consuming soy foods, has selective affinity for estrogen receptor-beta, whereas both enantiomers modulate androgen action. Little is known about the pharmacokinetics of the diastereoisomers, despite current interest in developing equol as a nutraceutical or pharmaceutical agent. OBJECTIVE: The objective was to compare the pharmacokinetics of S-(-)equol and R-(+)equol by using [13C] stable-isotope-labeled tracers to facilitate the optimization of clinical studies aimed at evaluating the potential of these diastereoisomers in the prevention and treatment of estrogen- and androgen-dependent conditions. DESIGN: A randomized, crossover, open-label study in 12 healthy adults (6 men and 6 women) compared the plasma and urinary pharmacokinetics of orally administered enantiomeric pure forms of S-(-)[2-13C]equol, R-(+)[2-13C]equol, and the racemic mixture. Plasma and urinary [13C]R-equol and [13C]S-equol concentrations were measured by tandem mass spectrometry. RESULTS:Plasma [13C]equol concentration appearance and disappearance curves showed that both enantiomers were rapidly absorbed, attained high circulating concentrations, and had a similar terminal elimination half-life of 7-8 h. The systemic bioavailability and fractional absorption of R-(+)[2-13C]equol were higher than those of S-(-)[2-13C]equol or the racemate. The pharmacokinetics of racemic (+/-)[2-13C]equol were different from those of the individual enantiomers: slower absorption, lower peak plasma concentrations, and lower systemic bioavailability. CONCLUSIONS: The high bioavailability of both diastereoisomers contrasts with previous findings for the soy isoflavones daidzein and genistein, both of which have relatively poor bioavailability, and suggests that low doses of equol taken twice daily may be sufficient to achieve biological effects.
RCT Entities:
BACKGROUND: The nonsteroidal estrogen equol occurs as diastereoisomers, S-(-)equol and R-(+)equol, both of which have significant biological actions. S-(-)equol, the naturally occurring enantiomer produced by 20-30% of adults consuming soy foods, has selective affinity for estrogen receptor-beta, whereas both enantiomers modulate androgen action. Little is known about the pharmacokinetics of the diastereoisomers, despite current interest in developing equol as a nutraceutical or pharmaceutical agent. OBJECTIVE: The objective was to compare the pharmacokinetics of S-(-)equol and R-(+)equol by using [13C] stable-isotope-labeled tracers to facilitate the optimization of clinical studies aimed at evaluating the potential of these diastereoisomers in the prevention and treatment of estrogen- and androgen-dependent conditions. DESIGN: A randomized, crossover, open-label study in 12 healthy adults (6 men and 6 women) compared the plasma and urinary pharmacokinetics of orally administered enantiomeric pure forms of S-(-)[2-13C]equol, R-(+)[2-13C]equol, and the racemic mixture. Plasma and urinary [13C]R-equol and [13C]S-equol concentrations were measured by tandem mass spectrometry. RESULTS: Plasma [13C]equol concentration appearance and disappearance curves showed that both enantiomers were rapidly absorbed, attained high circulating concentrations, and had a similar terminal elimination half-life of 7-8 h. The systemic bioavailability and fractional absorption of R-(+)[2-13C]equol were higher than those of S-(-)[2-13C]equol or the racemate. The pharmacokinetics of racemic (+/-)[2-13C]equol were different from those of the individual enantiomers: slower absorption, lower peak plasma concentrations, and lower systemic bioavailability. CONCLUSIONS: The high bioavailability of both diastereoisomers contrasts with previous findings for the soy isoflavonesdaidzein and genistein, both of which have relatively poor bioavailability, and suggests that low doses of equol taken twice daily may be sufficient to achieve biological effects.
Authors: Marjorie G Busby; A Robert Jeffcoat; LeAnne T Bloedon; Matthew A Koch; Tracy Black; Kelly J Dix; William D Heizer; Brian F Thomas; Judith M Hill; James A Crowell; Steven H Zeisel Journal: Am J Clin Nutr Date: 2002-01 Impact factor: 7.045
Authors: K Morito; T Hirose; J Kinjo; T Hirakawa; M Okawa; T Nohara; S Ogawa; S Inoue; M Muramatsu; Y Masamune Journal: Biol Pharm Bull Date: 2001-04 Impact factor: 2.233
Authors: Kenneth D R Setchell; Nadine Maynard Brown; Pankaj B Desai; Linda Zimmer-Nechimias; Brian Wolfe; Abhijeet S Jakate; Vivian Creutzinger; James E Heubi Journal: J Nutr Date: 2003-04 Impact factor: 4.798
Authors: Trent D Lund; Daniel J Munson; Megan E Haldy; Kenneth D R Setchell; Edwin D Lephart; Robert J Handa Journal: Biol Reprod Date: 2003-12-17 Impact factor: 4.285
Authors: LeAnne T Bloedon; A Robert Jeffcoat; Wlodek Lopaczynski; Michael J Schell; Tracy M Black; Kelly J Dix; Brian F Thomas; Craig Albright; Marjorie G Busby; James A Crowell; Steven H Zeisel Journal: Am J Clin Nutr Date: 2002-11 Impact factor: 7.045
Authors: Kenneth D R Setchell; Nadine M Brown; Xueheng Zhao; Stephanie L Lindley; James E Heubi; Eileen C King; Mark J Messina Journal: Am J Clin Nutr Date: 2011-09-28 Impact factor: 7.045
Authors: Nadine M Brown; Carrie A Belles; Stephanie L Lindley; Linda D Zimmer-Nechemias; Xueheng Zhao; David P Witte; Mi-Ok Kim; Kenneth D R Setchell Journal: Carcinogenesis Date: 2010-01-28 Impact factor: 4.944